Growth stabilization and regression of meningiomas after discontinuation of cyproterone acetate: a case series of 12 patients
- 12 August 2015
- journal article
- case report
- Published by Springer Science and Business Media LLC in Acta Neurochirurgica
- Vol. 157 (10), 1741-1746
- https://doi.org/10.1007/s00701-015-2532-3
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Hormone replacement therapy and risk of meningioma in women: a meta-analysisCancer Causes & Control, 2013
- Genomic Analysis of Non- NF2 Meningiomas Reveals Mutations in TRAF7 , KLF4 , AKT1 , and SMOScience, 2013
- Exogenous hormone use, reproductive factors, and risk of intracranial meningioma in femalesJournal of Neurosurgery, 2013
- Intracranial Meningiomas in Patients with Uterine Sarcoma Treated with Long-Term Megestrol Acetate TherapyWorld Neurosurgery, 2011
- Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population‐based cohort studyBritish Journal of Clinical Pharmacology, 2011
- Regression of meningiomas after discontinuation of cyproterone acetate in a transsexual patientActa Neurochirurgica, 2010
- Abrupt Regression of a Meningioma after Discontinuation of Cyproterone Treatment: Fig 1.American Journal of Neuroradiology, 2010
- Growth of a Meningioma in a Transsexual Patient after Estrogen–Progestin TherapyThe New England Journal of Medicine, 2007
- Multiple meningiomas arising during long-term therapy with the progesterone agonist megesterol acetateJournal of Neurosurgery, 2004
- Hormonal dependency of cerebral meningiomasJournal of Neurosurgery, 1990